About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Antisense and RNAi Therapeutics Market Size to Grow at a CAGR of 17.4% by 2032

Antisense and RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, siRNA, miRNA, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRPH56079DR
Author : Straits Research

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Antisense and RNAi Therapeutics Market Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    5. U.S.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Interference
          1. By Value
        3. siRNA
          1. By Value
        4. miRNA
          1. By Value
        5. Antisense RNA
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Cardiovascular Diseases (CVDs)
          1. By Value
        4. Respiratory Disorders
          1. By Value
        5. Renal Diseases
          1. By Value
        6. Neurodegenerative Disorders
          1. By Value
        7. Genetic Disorders
          1. By Value
        8. Infectious Diseases
          1. By Value
        9. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous Route
          1. By Value
        3. Subcutaneous Route
          1. By Value
        4. Intrathecal Route
          1. By Value
        5. Pulmonary Delivery
          1. By Value
        6. Intraperitoneal Injection
          1. By Value
        7. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    5. U.K.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Interference
          1. By Value
        3. siRNA
          1. By Value
        4. miRNA
          1. By Value
        5. Antisense RNA
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Cardiovascular Diseases (CVDs)
          1. By Value
        4. Respiratory Disorders
          1. By Value
        5. Renal Diseases
          1. By Value
        6. Neurodegenerative Disorders
          1. By Value
        7. Genetic Disorders
          1. By Value
        8. Infectious Diseases
          1. By Value
        9. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous Route
          1. By Value
        3. Subcutaneous Route
          1. By Value
        4. Intrathecal Route
          1. By Value
        5. Pulmonary Delivery
          1. By Value
        6. Intraperitoneal Injection
          1. By Value
        7. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    5. China
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Interference
          1. By Value
        3. siRNA
          1. By Value
        4. miRNA
          1. By Value
        5. Antisense RNA
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Cardiovascular Diseases (CVDs)
          1. By Value
        4. Respiratory Disorders
          1. By Value
        5. Renal Diseases
          1. By Value
        6. Neurodegenerative Disorders
          1. By Value
        7. Genetic Disorders
          1. By Value
        8. Infectious Diseases
          1. By Value
        9. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous Route
          1. By Value
        3. Subcutaneous Route
          1. By Value
        4. Intrathecal Route
          1. By Value
        5. Pulmonary Delivery
          1. By Value
        6. Intraperitoneal Injection
          1. By Value
        7. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    5. UAE
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Interference
          1. By Value
        3. siRNA
          1. By Value
        4. miRNA
          1. By Value
        5. Antisense RNA
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Cardiovascular Diseases (CVDs)
          1. By Value
        4. Respiratory Disorders
          1. By Value
        5. Renal Diseases
          1. By Value
        6. Neurodegenerative Disorders
          1. By Value
        7. Genetic Disorders
          1. By Value
        8. Infectious Diseases
          1. By Value
        9. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous Route
          1. By Value
        3. Subcutaneous Route
          1. By Value
        4. Intrathecal Route
          1. By Value
        5. Pulmonary Delivery
          1. By Value
        6. Intraperitoneal Injection
          1. By Value
        7. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Interference
        1. By Value
      3. siRNA
        1. By Value
      4. miRNA
        1. By Value
      5. Antisense RNA
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Cardiovascular Diseases (CVDs)
        1. By Value
      4. Respiratory Disorders
        1. By Value
      5. Renal Diseases
        1. By Value
      6. Neurodegenerative Disorders
        1. By Value
      7. Genetic Disorders
        1. By Value
      8. Infectious Diseases
        1. By Value
      9. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Subcutaneous Route
        1. By Value
      4. Intrathecal Route
        1. By Value
      5. Pulmonary Delivery
        1. By Value
      6. Intraperitoneal Injection
        1. By Value
      7. Others
        1. By Value
    5. Brazil
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Interference
          1. By Value
        3. siRNA
          1. By Value
        4. miRNA
          1. By Value
        5. Antisense RNA
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Cardiovascular Diseases (CVDs)
          1. By Value
        4. Respiratory Disorders
          1. By Value
        5. Renal Diseases
          1. By Value
        6. Neurodegenerative Disorders
          1. By Value
        7. Genetic Disorders
          1. By Value
        8. Infectious Diseases
          1. By Value
        9. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous Route
          1. By Value
        3. Subcutaneous Route
          1. By Value
        4. Intrathecal Route
          1. By Value
        5. Pulmonary Delivery
          1. By Value
        6. Intraperitoneal Injection
          1. By Value
        7. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Antisense and RNAi Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. GSK plc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Olix Pharmaceuticals, Inc.
    3. Sanofi
    4. Alnylam Pharmaceuticals, Inc.
    5. Arbutus Biopharma
    6. Benitec Biopharma Inc.
    7. Silence Therapeutics
    8. Ionis Pharmaceuticals, Inc
    9. Sarepta Therapeutics
    10. Percheron Therapeutics Limited
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Straits Research - Access Portal
  • 📊 Preview Report Scope and Structure – Gain immediate visibility into key topics, market segments, and data frameworks covered.
  • 📥 Evaluate Strategic Insights – Access selected charts, statistics, and analyst-driven commentary derived from the final report deliverables.
Get Free Access


We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.